“Inhibition of IRAK 1/4 alleviates colitis by inhibiting TLR4/ NF-κB pathway and protecting the intestinal barrier” (2022) Biomolecules and Biomedicine, 22(6), pp. 872–881. doi:10.17305/bjbms.2022.7348.